Coverage
-
December 18, 2020
Three days into a virtual bench trial in Delaware federal court, Bayer AG and MSN Laboratories on Friday proposed to end their legal fight over MSN's plans to market a generic version of one of Bayer's bestselling drugs, the high blood pressure medication Adempas.
1 other articles on this case.
View all »